Screener
Arcus Biosciences RCUS Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Arcus Biosciences’s reported figures.
Based on the most recent quarter.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's debt-to-equity?
- Arcus Biosciences (RCUS) reported debt-to-equity of 0.2× in Q2 2026.
- How has Arcus Biosciences's debt-to-equity changed year-over-year?
- Arcus Biosciences's debt-to-equity increased by 23.8% year-over-year, from 0.2× to 0.2×.
- What is the long-term trend for Arcus Biosciences's debt-to-equity?
- Over 5 years (2020 to 2025), Arcus Biosciences's debt-to-equity has grown at a 54.1% compound annual growth rate (CAGR), from 0× to 0.3×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Arcus Biosciences's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude